JP2012502071A - 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用 - Google Patents

急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用 Download PDF

Info

Publication number
JP2012502071A
JP2012502071A JP2011526411A JP2011526411A JP2012502071A JP 2012502071 A JP2012502071 A JP 2012502071A JP 2011526411 A JP2011526411 A JP 2011526411A JP 2011526411 A JP2011526411 A JP 2011526411A JP 2012502071 A JP2012502071 A JP 2012502071A
Authority
JP
Japan
Prior art keywords
receptor agonist
ang
peptide
lung injury
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502071A5 (enExample
Inventor
ヴァルター，トーマス
キューブラー，ヴォルフガング
Original Assignee
シャリテ−ウニヴェルズィテートメディツィーン ベルリン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャリテ−ウニヴェルズィテートメディツィーン ベルリン filed Critical シャリテ−ウニヴェルズィテートメディツィーン ベルリン
Publication of JP2012502071A publication Critical patent/JP2012502071A/ja
Publication of JP2012502071A5 publication Critical patent/JP2012502071A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011526411A 2008-09-12 2009-09-11 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用 Pending JP2012502071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08016142.5 2008-09-12
EP08016142A EP2163259B1 (en) 2008-09-12 2008-09-12 Use of an Ang-(1-7) receptor agonist in acute lung injury
PCT/EP2009/006619 WO2010028845A2 (en) 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013257932A Division JP5881122B2 (ja) 2008-09-12 2013-12-13 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用

Publications (2)

Publication Number Publication Date
JP2012502071A true JP2012502071A (ja) 2012-01-26
JP2012502071A5 JP2012502071A5 (enExample) 2013-05-16

Family

ID=40430691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011526411A Pending JP2012502071A (ja) 2008-09-12 2009-09-11 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用
JP2013257932A Expired - Fee Related JP5881122B2 (ja) 2008-09-12 2013-12-13 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013257932A Expired - Fee Related JP5881122B2 (ja) 2008-09-12 2013-12-13 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用

Country Status (9)

Country Link
US (4) US20110281805A1 (enExample)
EP (2) EP2163259B1 (enExample)
JP (2) JP2012502071A (enExample)
KR (1) KR20110074978A (enExample)
CN (2) CN102164614B (enExample)
BR (2) BR122013002187A2 (enExample)
CA (1) CA2736922C (enExample)
ES (1) ES2393455T3 (enExample)
WO (1) WO2010028845A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532291A (ja) * 2012-10-02 2015-11-09 タリックス ファーマシューティカルズ リミテッド 脳状態の処置におけるアンジオテンシン
JP2016522178A (ja) * 2013-04-19 2016-07-28 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 筋ジストロフィーにおけるアンジオテンシン
JP2017521390A (ja) * 2014-07-17 2017-08-03 ユニバーシティー オブ サウザン カリフォルニア 筋骨格系疾患の治療のための方法、化合物、および組成物

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury
CN104302305A (zh) * 2011-12-16 2015-01-21 塔瑞克斯制药有限公司 用于治疗纤维化的血管紧张素
CN102532265A (zh) * 2011-12-29 2012-07-04 中国人民解放军第四军医大学 一种短肽、其异构体及其应用
CA2863699A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
AU2013315004A1 (en) * 2012-09-17 2015-04-02 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
EP3003345A4 (en) 2013-05-24 2017-03-01 Tarix Pharmaceuticals Ltd. Angiotensin peptides in treating marfan syndrome and related disorders
WO2015054005A1 (en) * 2013-10-11 2015-04-16 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of bdnf-related conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
WO2016014342A2 (en) 2014-07-21 2016-01-28 Arizona Board Of Regents For The University Of Arizona Ang-(1-7) derviative oligopeptides and methods for using and producing the same
EP3281133A1 (en) * 2015-04-08 2018-02-14 Koninklijke Philips N.V. Tool for recommendation of ventilation therapy guided by risk score for acute respirator distress syndrome (ards)
WO2018129511A2 (en) * 2017-01-09 2018-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) and derivative oligopeptides for the treatment of traumatic brain injury and other cognitive impairments
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
CN112316107B (zh) * 2019-07-17 2023-01-06 首都医科大学附属北京妇产医院 血管紧张素(1-7)在胰腺疾病中的应用
EP4117703A1 (en) * 2020-03-13 2023-01-18 Constant Therapeutics LLC Methods and compositions for treatment of coronavirus infection
WO2022094025A1 (en) * 2020-10-30 2022-05-05 Gere Dizerega Angiotensin-1-7 for the treatment of covid-19
MX2023008832A (es) 2021-01-28 2023-10-23 Capacity Bio Inc Métodos y agentes que estimulan el recambio mitocondrial para el tratamiento de enfermedades.
EP4085921A1 (en) 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensin-(1-7) in the treatment of sars-cov related diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018792A2 (en) * 2006-08-08 2008-02-14 Applied Nanosystems B.V. Cyclic angiotensin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
EP1485116A4 (en) * 2002-02-27 2006-06-07 Univ Wake Forest ANGIOTENSIN- (1-7) AND AGONISTS OF ANGIOTENSIN- (1-7) FOR THE INHIBITION OF GROWTH OF CANCER CELLS
US20050119180A1 (en) * 2002-03-28 2005-06-02 Roks Antonius J.M. Use of angiotensin 1-7 for enhancing cardiac function
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
BRPI0503122A (pt) 2005-05-30 2007-05-02 Univ Minas Gerais composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018792A2 (en) * 2006-08-08 2008-02-14 Applied Nanosystems B.V. Cyclic angiotensin analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5011012990; ＪＩＡＮＧ　ＪＩＵＮＮ-ＳＯＮＧ: 'ＡＮＧＩＯＴＥＮＳＩＮ-ＣＯＮＶＥＲＴＩＮＧ　ＥＮＺＹＭＥ　ＩＮＨＩＢＩＴＯＲ　ＣＡＰＴＯＰＲＩＬ　ＡＴＴＥＮＵＡＴＥＳ　ＶＥＮＴＩＬＡＴＯＲ-ＩＮＤＵＣＥＤ　ＬＵＮＧ　ＩＮＪＵＲＹ　ＩＮ　ＲＡＴＳ' ＪＯＵＲＮＡＬ　ＯＦ　ＡＰＰＬＩＥＤ　ＰＨＹＳＩＯＬＯＧＹ Ｖ１０２　Ｎ６, 200706, Ｐ２０９８-２１０３ *
JPN5011012991; ＳＡＮＴＯＳ　ＲＯＢＳＯＮ　Ａ　Ｓ: 'ＰＨＡＲＭＡＣＯＬＯＧＩＣＡＬ　ＥＦＦＥＣＴＳ　ＯＦ　ＡＶＥ　０９９１，Ａ　ＮＯＮＰＥＰＴＩＤＥ　ＡＮＧＩＯＴＥＮＳＩＮ-（１-７）ＲＥＣＥＰＴＯＲ　ＡＧＯＮＩＳＴ' ＣＡＲＤＩＯＶＡＳＣＵＬＡＲ　ＤＲＵＧ　ＲＥＶＩＥＷＳ Ｖ２４　Ｎ３-４, 200610, Ｐ２３９-２４６ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015532291A (ja) * 2012-10-02 2015-11-09 タリックス ファーマシューティカルズ リミテッド 脳状態の処置におけるアンジオテンシン
JP2018090625A (ja) * 2012-10-02 2018-06-14 タリックス ファーマシューティカルズ リミテッド 脳状態の処置におけるアンジオテンシン
JP2016522178A (ja) * 2013-04-19 2016-07-28 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 筋ジストロフィーにおけるアンジオテンシン
JP2017521390A (ja) * 2014-07-17 2017-08-03 ユニバーシティー オブ サウザン カリフォルニア 筋骨格系疾患の治療のための方法、化合物、および組成物

Also Published As

Publication number Publication date
US20160051621A1 (en) 2016-02-25
US8383772B2 (en) 2013-02-26
WO2010028845A3 (en) 2010-06-10
US20110281805A1 (en) 2011-11-17
US20120321701A1 (en) 2012-12-20
KR20110074978A (ko) 2011-07-05
EP2163259A1 (en) 2010-03-17
CA2736922A1 (en) 2010-03-18
ES2393455T3 (es) 2012-12-21
JP5881122B2 (ja) 2016-03-09
BRPI0918443A2 (pt) 2015-11-24
US20140073760A1 (en) 2014-03-13
EP2163259B1 (en) 2012-06-13
CN102164614A (zh) 2011-08-24
JP2014074048A (ja) 2014-04-24
BR122013002187A2 (pt) 2016-04-05
WO2010028845A2 (en) 2010-03-18
CA2736922C (en) 2014-08-19
EP2341938A2 (en) 2011-07-13
CN102164614B (zh) 2014-03-26
HK1161100A1 (en) 2012-08-24
CN103263661A (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
JP5881122B2 (ja) 急性肺損傷におけるａｎｇ−（１−７）レセプターアゴニストの使用
JP6962943B2 (ja) 腎不全を処置するための組成物及び方法
EP2986308B1 (en) Angiotensin ii in combination for the treatment of hypotension
JP2011241214A (ja) 線維症の処置におけるＣ５ａ受容体アンタゴニストの使用
TWI688385B (zh) 治療低血壓之方法
CN103717219A (zh) 左心室舒张功能改善剂
TW201733610A (zh) 投與血管收縮素ｉｉ之方法
BR112021002920A2 (pt) composições e métodos para tratamento de lesão pulmonar aguda
JP5477794B2 (ja) エンドキニンｃ／ｄ由来のペプチド
WO2020211772A1 (en) Purmorphamine as a small compound positive allosteric modulator of secretin receptor for the treatment of hypertension
US20250235502A1 (en) Cardio-protective effect of vasoconstriction-inhibiting factor (vif)
HK1161100B (en) Use of an ang-(1-7) receptor agonist in acute lung injury
CN106061495B (zh) 肺内炎症的减弱
CN120187434A (zh) 用于治疗脓毒症的奥塞吉泮
Shenoy et al. Conflict of interest: None Correspondence to

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130329

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20130329

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20130411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130813